Buyers of Zetia seek class recertification after 4th circ ruling
28-09-2021
MSD and Glenmark appeal pay-for-delay Zetia dispute
07-01-2021
Vitalii Vodolazskyi / Shutterstock.com
A Virginia district court judge has recommended that buyers of cholesterol drug Zetia (ezetimibe) should not be granted class certification in pay-for-delay litigation against MSD (known as 'Merck & Co' in the US) and Glenmark Generics.
To continue reading this article and to access our full archive, digital magazines and special reports you will need a subscription.
Start a subscription today to access the LSIPR website
If you have already subscribed please login.
For multi-user price options, or to check if your company has an existing subscription we can add you into, please email Atif at achoudhury@newtonmedia.co.uk
If you have any technical issues please email tech support.
For access to the complete website and archive choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial select ‘TWO WEEK FREE TRIAL’.
US Court of Appeals for the Fourth Circuit, US District Court for the Eastern District of Virginia, generics, pay-for-delay, antitrust, Zetia
